An Overview of HPV Screening Assessments to Enhance Entry to Cervical Cance


Cervical most cancers is a serious public well being drawback and is the fourth most typical most cancers in ladies worldwide accounting for an estimated 604,000 new instances every year.1 Greater than 80% of the worldwide burden of cervical most cancers happens within the low- and middle-income international locations (LMIC) of sub-Saharan Africa and Asia, the place it accounts for about 12% of all feminine cancers.2 In 2020, an estimated 342,000 deaths had been on account of cervical most cancers thus accounting for 7.5% of cancer-related deaths in females.1 Practically 9 in ten of those deaths happen within the LMICs.1,3 Data of the pure historical past and aetiology of cervical most cancers has now provided a singular alternative to forestall the illness.4 To eradicate the substantial world burden and the growing inequity related to cervical most cancers, the World Well being Group (WHO) Director-Common made a name in Could 2018 for world motion for the introduction of a triple-intervention technique referred to as 90–70–90 targets: (1.) to vaccinate 90% of all ladies by age 15 years, (2.) to display screen 70% of girls twice by age 35 and 45 years, and (3.) to deal with at the least 90% of all precancerous and cancerous lesions detected throughout screening.5 That is projected to end in a worldwide threshold of 4 new instances per 100,000 women-year comparable to greater than 74 million instances and greater than 62 million deaths averted over the subsequent century.6 This means that cervical most cancers is sort of utterly preventable by way of extremely efficient major (HPV vaccination) and secondary (screening) prevention measures.1 In 2019, WHO recommends high-quality screening applications concentrating on ladies aged 30 to 49 years, similar to visible inspection with acetic acid in resource-constrained settings, a Papanicolaou (Pap) smear check each 3 to five years, or HPV testing each 5 years, coupled with well timed and efficient therapy of precancerous lesions.7 As rising proof at present helps using HPV-based exams as the popular major screening check for the detection of precancerous lesions,5,8 there’s an pressing must construct a extra equitable future and eradicate the health-care disparities which will have an effect on the efficient introduction of this high-performance screening check5 in underserved populations. Subsequently, this assessment will give attention to figuring out these vital challenges to testing after which suggest efficient methods for its profitable implementation.

The Hyperlink Between Human Papillomavirus and Cervical Most cancers

Persistent genital an infection with sure forms of HPV has been reported as a crucial reason for cervical most cancers.9 The energy of the affiliation between HPV an infection and cervical squamous cell carcinoma is increased than that of the affiliation reported between smoking and lung most cancers.10 HPV infections are, nonetheless, much less generally associated to adenocarcinomas of the cervix as solely about 43% of instances seen in ladies aged 60 years and older are related to the an infection.10 HPV are carefully associated viruses which are categorized and numbered primarily based on their nucleic acid sequencing and order of discovery, respectively.10 Greater than 200 HPV varieties are recognized to exist in people11,12 with about 30 of those transmitted throughout sexual contact to the genital areas the place 14 varieties (categorized as group 1 carcinogens) are related to cervical most cancers.9 Not less than one in every of these HPV varieties is implicated in virtually all instances of cervical squamous cell carcinoma.9 Because of its causal relationship with cervical most cancers and its precursor lesions, genital HPV an infection will be grouped as non-oncogenic and oncogenic HPV varieties.9,10 Non-oncogenic HPV embrace varieties 6, 11, 42, 43, and 44 whereas the oncogenic varieties are 16, 18, 31, 33, 34, 39, 45, 51, 52, 56, 58, 59, 66, and 68.9 The virus often infects matured mucocutaneous epithelial cells of the cervix to provide viral particles that disrupt the conventional cell-cycle management inflicting the promotion of uncontrolled cell division that results in genetic injury.11 Generally, the event of a productive HPV-related lesion requires that the virus entry the epithelial basal layer as soon as the epithelial barrier has been breached.13 The detection of oncogenic HPV an infection within the cervix is important however is probably not sufficient for the event of cervical most cancers.9 It is because most HPV-induced cervical modifications are transient with about 90% clearing spontaneously inside 2 years.14 Subsequently, the presence of things that alter a girl’s skill to clear the virus10 similar to a person’s genetic predisposition and immune standing,15 genetic variations in HPV varieties, an infection with multiple oncogenic HPV kind, and frequency of HPV reinfection10 will decide whether or not or not the lady develops cervical most cancers.

Fundamental Virology of HPV

HPV is a comparatively small, non-enveloped virus of about 55 nm in diameter.10 Every virus has an icosahedral capsid containing 72 capsomers with at the least two capsid proteins, L1 and L2. Every of those capsomers is a pentamer of the most important capsid protein, L1.16 Every of the most important virion capsids accommodates about 12 copies of the minor capsid protein, L2.17 HPV consists of a single-molecule of round, double-stranded DNA18 with a genome containing all Open Studying Body (ORF) protein-coding sequences confined to one of many strands.19 The HPV genome consists of three useful areas:19 (1.) The lengthy management area (LCR) known as the “non-coding upstream regulatory area (URR)” accommodates the best diploma of variation within the HPV genome. It accommodates the p97 core promoter together with enhancer and silencer sequences that management ORFs transcription for the regulation of DNA replication;20 (2.) The “early area (E)” consists of ORFs E1, E2, E4, E5, E6, and E7, which management viral replication and tumorigenesis; and (3.) The “late area (L)” encodes the L1 and L2 structural proteins for the viral capsid (Determine 1).19 A brand new HPV kind ought to have nucleotide sequences of the E6, E7, and L1 ORFs which are not more than 90% homologous to the corresponding sequences of any of the prevailing HPV kind.10

Determine 1 Fundamental virology of HPV. Used with permission of Portland Press, Ltd. from Stanley MA, Pett MR, Coleman N. HPV: from an infection to most cancers. Biochem Soc Trans. 2007;35(Pt 6):1456–1460; permission converyed by way of Copyright Clearance Heart, Inc.19

Improvement of HPV Screening Assessments

Cervical most cancers screening includes testing for HPV an infection and precursor cervical most cancers lesions amongst ladies with no signs, and when screening detects cervical pre-cancerous lesions, therapy can simply be instituted, and most cancers averted.10 The event of HPV screening exams is without doubt one of the handiest methods for cervical most cancers management.10 The laboratory tradition of HPV will not be dependable; nonetheless, by way of using molecular-based applied sciences, HPV DNA or HPV E6/E7 mRNA will be detected in cervical/vaginal samples.21 The molecular methods for HPV DNA detection will be categorized broadly into these applied sciences that aren’t amplified, similar to direct genome detection exams or nucleic acid probe exams, and those who make the most of amplification, each conventionally and in real-time, to acquire DNA copies. Amplification strategies will also be divided into three totally different teams: (1.) goal amplification – which includes amplification of the goal nucleic acids (for instance, polymerase chain response – PCR); (2.) sign amplification – which includes amplification of the sign generated from every probe by a compound-probe or branched-probe expertise; and (3.) probe amplification – which includes the probe molecule amplification (for instance, ligase chain response – LCR). Conversely to the DNA detection methodology, the mRNA exams determine the expression of HPV E6 and E7 oncoproteins that regulate the oncogenic technique of cervical most cancers. The detection of E6/E7 oncogene expression may very well be a extra particular and higher most cancers danger predictor than the HPV-DNA exams.22

Many earlier research of HPV usually use nucleic acid amplification strategies that generate genotype-specific outcomes.23 The PCR assays particularly goal genetically conserved areas within the L1 gene to detect the HPV DNA of any of the 14 HPV varieties which are recognized to trigger cervical most cancers in cervical epithelial cells.9 The detection of 1 or any mixture of those HPV varieties will end in a optimistic check end result. The assays for detecting HPV an infection differ of their sensitivity and type-specificity,22 relying on the anatomic area sampled, in addition to the tactic of specimen assortment.24 With out the data of particular HPV varieties in a screening pattern, many ladies will bear pointless follow-up and therapy as totally different HPV varieties carry a distinct danger of cervical most cancers.25 Virus-like-particle-(VLP)-based enzyme immunoassays are essentially the most often used HPV serologic assays; nonetheless, there are not any standardized reagents for these assays within the laboratory and there are additionally no requirements for setting a threshold for a optimistic end result. Subsequently, serology-based HPV exams should not utilized in scientific apply.24 As well as, not one of the commercially accessible molecular-based HPV exams is clinically indicated nor accredited to be used in males.22

Implementation of HPV Screening Assessments

Probably the most applicable HPV check ought to be chosen to be used in a cervical most cancers screening programme, particularly in underserved settings primarily based on consideration for efficiency accuracy, scientific validation, prices, and different operational and logistical necessities similar to provide chain administration and storage.22 The direct detection of HPV DNA in cervical or vaginal samples ought to be used as a substitute or to enhance a population-based cytological screening programme.10 It is because HPV-based screening exams are extra delicate than cytology or VIA as a major screening methodology and are much more clinically priceless for triaging gentle cytological abnormalities as a hybrid check.10 These screening methods decrease the necessity for pointless follow-up analysis, particularly in settings with restricted or no entry to colposcopy.

  1. Hybrid HPV screening: Cervical most cancers screening programmes in each developed and growing international locations have relied totally on cytological-based testing similar to Pap smear exams. Nevertheless, due to the decrease specificity of Pap smear,8,26,27 ladies with gentle cytological abnormalities10 similar to atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesions (LSIL)28,29 are required to bear triaging utilizing the extra particular molecular-based HPV screening exams in a hybrid strategy earlier than referral for colposcopy if optimistic for any of the oncogenic HPV varieties. Nevertheless, primarily based on the timing of the triage screening check, hybrid HPV exams are categorized as (1.) Pap Smear/HPV co-test includes the simultaneous efficiency of cervical cytology and HPV DNA testing utilizing the pattern of cells eliminated throughout a Liquid Based mostly Cytology (LBC), and (2.) HPV reflex testing includes the efficiency of an HPV check utilizing cells from the pattern eliminated throughout an LBC. Ladies with gentle cytological abnormalities who check destructive for HPV an infection will bear repeat cytology testing after 12 months whereas those that check optimistic for any type-specific oncogenic HPV kind(s) can be referred for rapid colposcopy analysis.30
  2. Major HPV check: That is utilizing the HPV check as a first-line screening methodology. HPV exams have a better sensitivity than cytology (96.1% vs 53.0%) however decrease specificity (90.7% versus 96.3%).8 Though it’s extremely delicate, HPV testing can not discriminate between transient and protracted infections,31 and thus it is just higher suited as a screening check.32 The Worldwide Company for Analysis on Most cancers (IARC)33 and the WHO5 have now really useful HPV exams as the first methodology for the detection of precancerous lesions of the cervix.8 Subsequently, the first HPV screening check has now changed different screening modalities in virtually all developed international locations and plenty of growing international locations.8,31,34,35 Though, it has a better value than different screening exams, it’s more cost effective in detecting precancerous lesions of the cervix when carried out in an organised setting8 that’s accompanied by a robust health-infrastructure framework. A destructive HPV check end result supplies higher reassurance towards the event of high-grade precancerous lesions with protected prolongation of screening intervals.31 A destructive check end result signifies a low likelihood of growing high-grade precancerous and cancerous lesions within the subsequent 5–10 years with excessive accuracy.36 A secondary or intermediate check, subsequently, must be developed and carried out to keep away from the pointless, invasive, uncomfortable, and expensive procedures which will accompany an HPV-based screening programme. This inexpensive and available check is important to segregate or triage clinically unimportant HPV infections that don’t require colposcopy37 by optimizing specificity, with out sacrificing sensitivity.38,39 The seek for essentially the most applicable check continues, nonetheless, in most elements of the world, the Pap smear check is at present used to triage oncogenic HPV-positive ladies who’re destructive for HPV16 or 18. Ladies who check optimistic for HPV an infection are both referred straight for colposcopy (if optimistic for HPV varieties 16/18) or cervical cytology earlier than colposcopy (if optimistic for one or any mixture of the remaining 12 oncogenic HPV varieties) when crucial.35 This isn’t but a scalable answer; nonetheless, it is a vital space that requires additional investigation to determine essentially the most appropriate intermediate or secondary check that might forestall low-risk sufferers from present process pointless invasive procedures or extra follow-up visits.

Overcoming Challenges of Implementation of HPV-Based mostly Cervical Most cancers Screening Programme in Underserved Populations

  1. Programmatic issues: Cervical most cancers is now primarily a illness of marginalized and underserved ladies, notably these within the LMICs of Africa and Southeast Asia.40 At present, solely 44% of girls in resource-limited international locations have ever been screened for cervical most cancers, with the bottom prevalence (0.9–50.8%) amongst ladies in sub-Saharan Africa,41 in contrast with over 60% in high-income international locations (HIC).6 The underserved ladies in these resource-limited international locations typically lack entry to the assets essential to implement profitable cervical most cancers prevention programmes.4 As well as, these international locations typically have restricted funds and most cancers screening applications often compete with different urgent well being wants.42 Moreover, ladies who’re on the highest danger of cervical most cancers in most LMIC settings typically lack entry to related info and companies crucial to guard them from growing the illness.33
  2. Challenges of HPV-based screening implementation: There was a gradual shift from HPV reflex testing for gentle cytological abnormalities to Pap smear/HPV co-test paradigm, and now to major HPV testing.31 All these screening approaches face widespread challenges to profitable implementation similar to logistic and infrastructure inadequacies, value considerations, poor follow-up, and sociocultural constraints.43 A broad array of social, cultural, and scientific elements might affect the place, how, or if cervical most cancers screening companies will be efficiently supplied. Despite the fact that HPV-based screening programmes have varied benefits, the sensible implementation is fraught with substantial challenges, particularly in resource-limited settings.43 HPV-based screening programmes face a number of selections concerning the programme design similar to the selection of HPV check, triage methodology, follow-up and referral advice, goal age vary, screening interval, communication technique, and coaching technique for health-care suppliers.44 The optimum selections in underserved settings will, subsequently, depend upon the nationwide and native context, together with the provision of monetary assets, technical capability and laboratory infrastructure.44,45 Whatever the chosen testing methodology, it is very important be sure that ladies with screen-positive precancerous and cancerous lesions be adequately handled as it’s unethical to supply screening with out entry to therapy.5
  3. Overcoming implementation challenges of HPV-based screening exams: Regardless of its cost-effectiveness, an HPV-based screening check per see will not be sufficient to beat the challenges of a fragile health-care construction. Earlier than incorporating HPV exams right into a screening programme, a radical understanding of the complexities of the check have to be fastidiously thought-about. Along with its increased sensitivity than different accessible screening exams, the most important benefit of HPV testing is its excessive and long-lasting destructive predictive worth and its prolonged screening intervals of at the least 5 years.8 The American Most cancers Society, subsequently, recommends that girls provoke cervical most cancers screening at age 30 years (or 25 years for average-risk individuals) and bear major HPV testing each 5 years by way of age 65 years as a most popular possibility.46 To additional decrease the price and frequency of testing with out compromising illness detection, particularly in settings with restricted screening capability, WHO has really useful, as a part of its world methods to eradicate cervical most cancers, {that a} lady undergoes two HPV screening exams at 35 and 45 years of age to confer substantial lifetime preventive profit.5,47 Till not too long ago, the most important obstacles to using HPV-based molecular testing in most resource-constrained settings are the necessity for costly laboratory infrastructure and the extended time required to course of check outcomes.10 The event of the fast molecular-based testing strategies screening for cervical most cancers screening is a milestone for the low-resource settings because of the excessive laboratory throughput and pointless necessities for big infrastructure.36 Moreover, HPV screening exams now provide a singular alternative for self-sampling to ladies who stay in distant areas or who’re reluctant to bear gynaecological examination for pattern assortment by physicians.48 Self-sampled HPV testing provides an economical screening technique by growing the extent of screening attendance, reducing the price of testing, and attracting extra unscreened or under-screened ladies.49,50 Lastly, to beat the substantial loss to follow-up in ladies present process repeat cervical most cancers screenings for monitoring, HPV-based exams can now be safely carried out utilizing a “see-and-treat” strategy in a point-of-care platform that requires restricted abilities of laboratory technicians.51 On this occasion, HPV screening, triage, and therapy will be supplied collectively in a single go to.5,47


In recent times, the incidence and deaths from cervical most cancers have decreased considerably in high-income international locations (HICs) largely because of the widespread implementation of screening programmes.9 Nevertheless, solely 44% of girls in LMICs have ever been screened41 in contrast with over 60% in HICs.6 WHO now recommends that girls be screened often for cervical illness with a high-performance check similar to an HPV-based molecular check and that is to exchange the extensively used Pap smear and visible inspection with acetic acid (VIA).5 Nevertheless, there are a number of challenges dealing with the sensible implementation of an HPV-based screening programme in underserved settings similar to the selection of HPV check, triage methodology, goal age vary, screening interval, follow-up and referral advice, communication methods, non-availability of monetary assets, technical capability, and laboratory infrastructure.44,45 Proposed measures to beat these challenges with out compromising illness detection in ladies in underserved settings embrace a discount in screening frequency utilizing the WHO world technique by providing screening solely twice to ladies at 35 and 45 years of age,5,47 fast turnover time of check outcomes,10 improved entry to vaginal self-sampling HPV testing for ladies in distant settings or those that are reluctant to bear gynaecological examination,48 and implementation of a “see-and-treat” strategy utilizing a point-of-care platform that required restricted abilities of laboratory technicians.51 All these methods can be of considerable profit to underserved populations, particularly amongst ladies residing in distant areas of Africa and Southeast Asia, the place ladies might must journey lengthy distances for screening and therapy, and the place there are restricted or no entry to technical and laboratory assets. As well as, the event and large-scale incorporation of extra particular HPV testing applied sciences which are less expensive and simpler to make use of in non-laboratory settings than the at present accessible choices ought to be prioritized for underserved settings. On the identical time, there’s a must develop and start the implementation of an inexpensive and available intermediate or secondary check with optimum specificity for triaging or segregating clinically unimportant HPV infections that don’t require colposcopy.37


This work was supported partly by way of the protected time provided by the Fogarty Worldwide Heart of the Nationwide Institutes of Well being (below Award Numbers K43TW011930, D43TW010934, D43TW010134, and D43TW010543). The views expressed on this publication are these of the authors and don’t essentially mirror the official views of the Nationwide Institutes of Well being.


The authors report no conflicts of curiosity on this work.


1. Sung H, Ferlay J, Siegel RL, et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660

2. Mohammed SI, Ren W, Flowers L, et al. Level-of-care check for cervical most cancers in LMICs. Oncotarget. 2016;7(14):18787–18797. doi:10.18632/oncotarget.7709

3. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical most cancers in 2018: a worldwide evaluation. Lancet Glob Well being. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6

4. Denny L. Cervical most cancers: prevention and therapy. Discov Med. 2012;14(75):125–131.

5. World Well being Group. world technique to speed up the elimination of cervical most cancers as a public well being drawback; 2020. Obtainable from: Accessed September 14, 2022.

6. Canfell Okay, Kim JJ, Brisson M, et al. Mortality affect of attaining WHO cervical most cancers elimination targets: a comparative modelling evaluation in 78 low-income and lower-middle-income international locations. Lancet. 2020;395(10224):591–603. doi:10.1016/S0140-6736(20)30157-4

7. World Well being Group. WHO pointers for using thermal ablation for cervical pre-cancer lesions; 2019.

8. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical most cancers: follow-up of 4 European randomised managed trials. Lancet. 2014;383(9916):524–532. doi:10.1016/S0140-6736(13)62218-7

9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a crucial reason for invasive cervical most cancers worldwide. J Pathol. 1999;189(1):12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

10. Okunade KS. Human papillomavirus and cervical most cancers. J Obstet Gynaecol. 2020;40(5):602–608. doi:10.1080/01443615.2019.1634030

11. Unger ER, Barr E. Human papillomavirus and cervical most cancers. Emerg Infect Dis. 2004;10(11):2031–2032. doi:10.3201/eid1011.040623_09

12. Burd EM. Human papillomavirus and cervical most cancers. Clin Microbiol Rev. 2003;16(1):1–17. doi:10.1128/CMR.16.1.1-17.2003

13. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus an infection. Nat Rev Dis Primers. 2016;2(1):16086. doi:10.1038/nrdp.2016.86

14. Quinlan JD. Human papillomavirus: screening, testing, and prevention. Am Fam Doctor. 2021;104(2):152–159.

15. de Araujo Souza PS, Villa LL. Genetic susceptibility to an infection with human papillomavirus and improvement of cervical most cancers in ladies in Brazil. Mutat Res. 2003;544(2–3):375–383. doi:10.1016/j.mrrev.2003.06.013

16. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Buildings of bovine and human papillomaviruses. Evaluation by cryoelectron microscopy and three-dimensional picture reconstruction. Biophys J. 1991;60(6):1445–1456. doi:10.1016/S0006-3495(91)82181-6

17. Sapp M, Volpers C, Müller M, Streeck RE. Group of the most important and minor capsid proteins in human papillomavirus kind 33 virus-like particles. J Gen Virol. 1995;76(Pt 9):2407–2412. doi:10.1099/0022-1317-76-9-2407

18. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol. 1975;15(5):1239–1247. doi:10.1128/JVI.15.5.1239-1247.1975

19. Stanley MA, Pett MR, Coleman N. HPV: from an infection to most cancers. Biochem Soc Trans. 2007;35(Pt 6):1456–1460. doi:10.1042/BST0351456

20. Apt D, Watts RM, Suske G, Bernard HU. Excessive Sp1/Sp3 ratios in epithelial cells throughout epithelial differentiation and mobile transformation correlate with the activation of the HPV-16 promoter. Virology. 1996;224(1):281–291. doi:10.1006/viro.1996.0530

21. Dabeski D, Duvlis S, Basheska N, et al. Comparability between HPV DNA testing and HPV E6/E7 MRNA testing in ladies with squamous cell abnormalities of the uterine cervix. Pril. 2019;40(1):51–58. doi:10.2478/prilozi-2019-0003

22. Cuzick J, Cadman L, Mesher D, et al. Evaluating the efficiency of six human papillomavirus exams in a screening inhabitants. Br J Most cancers. 2013;108(4):908–913. doi:10.1038/bjc.2013.22

23. Okunade KS, Nwogu CM, Oluwole AA, Anorlu RI. Prevalence and danger elements for genital high-risk human papillomavirus an infection amongst ladies attending the outpatient clinics of a college educating hospital in Lagos, Nigeria. Pan Afr Med J. 2017;28. doi:10.11604/pamj.2017.28.227.13979.

24. Meites E, Gee J, Unger E, Markowitz L. Human Papillomavirus: chapter 11. In: Epidemiology and Prevention of Vaccine-Preventable Illness. 14th ed.; 2021. Obtainable from:

25. Bonde JH, Sandri MT, Gary DS, Andrews JC. Medical utility of human papillomavirus genotyping in cervical most cancers screening: a scientific assessment. J Low Genit Tract Dis. 2020;24(1):1–13. doi:10.1097/LGT.0000000000000494

26. Wright TC. HPV DNA testing for cervical most cancers screening. Int J Gynaecol Obstet. 2006;95(Suppl 1):S239–S246. doi:10.1016/S0020-7292(06)60039-8

27. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American research on HPV testing in major cervical most cancers screening. Int J Most cancers. 2006;119(5):1095–1101. doi:10.1002/ijc.21955

28. Massad LS, Einstein MH, Huh WK, et al. 2012 up to date consensus pointers for the administration of irregular cervical most cancers screening exams and most cancers precursors. Obstet Gynecol. 2013;121(4):829–846. doi:10.1097/AOG.0b013e3182883a34

29. Saslow D, Solomon D, Lawson HW, et al. American Most cancers Society, American Society for Colposcopy and Cervical Pathology, and American Society for Medical Pathology screening pointers for the prevention and early detection of cervical most cancers. Am J Clin Pathol. 2012;137(4):516–542. doi:10.1309/AJCPTGD94EVRSJCG

30. Massad LS, Xie X, D’Souza G, et al. Incidence of cervical precancers amongst HIV-seropositive ladies. Am J Obstet Gynecol. 2015;212(5):606.e1–8. doi:10.1016/j.ajog.2014.12.003

31. Bhatla N, Singhal S. Major HPV screening for cervical most cancers. Finest Pract Res Clin Obstet Gynaecol. 2020;65:98–108. doi:10.1016/j.bpobgyn.2020.02.008

32. Wright TC, Massad LS, Dunton CJ, et al. 2006 consensus pointers for the administration of girls with irregular cervical most cancers screening exams. Am J Obstet Gynecol. 2007;197(4):346–355. doi:10.1016/j.ajog.2007.07.047

33. Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical most cancers screening. N Engl J Med. 2021;385(20):1908–1918. doi:10.1056/NEJMsr2030640

34. Leinonen MK, Nieminen P, Lönnberg S, et al. Detection charges of precancerous and cancerous cervical lesions inside one screening spherical of major human papillomavirus DNA testing: potential randomised trial in Finland. BMJ. 2012;345:e7789. doi:10.1136/bmj.e7789

35. Huh WK, Ault KA, Chelmow D, et al. Use of major high-risk human papillomavirus testing for cervical most cancers screening: interim scientific steering. Gynecol Oncol. 2015;136(2):178–182. doi:10.1016/j.ygyno.2014.12.022

36. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical most cancers screening in growing international locations at a crossroad: rising applied sciences and coverage selections. World J Clin Oncol. 2015;6(6):281–290. doi:10.5306/wjco.v6.i6.281

37. Tota JE, Bentley J, Blake J, et al. Approaches for triaging ladies who check optimistic for human papillomavirus in cervical most cancers screening. Prev Med. 2017;98:15–20. doi:10.1016/j.ypmed.2016.11.030

38. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. HPV DNA testing in population-based cervical screening (VUSA-Display screen research): outcomes and implications. Br J Most cancers. 2012;106(5):975–981. doi:10.1038/bjc.2011.581

39. Citadel PE, Gage JC, Wheeler CM, Schiffman M. The scientific that means of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol. 2011;118(6):1222–1229. doi:10.1097/AOG.0b013e318237caf4

40. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical most cancers. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X

41. Lemp JM, de Neve JW, Bussmann H, et al. Lifetime prevalence of cervical most cancers screening in 55 low- and middle-income international locations. JAMA. 2020;324(15):1532–1542. doi:10.1001/jama.2020.16244

42. World Well being Organiation. Cervical most cancers management in growing international locations: memorandum from a WHO assembly. Bull World Well being Organ. 1996;74(4):345–351.

43. Pimple SA, Mishra GA. International methods for cervical most cancers prevention and screening. Minerva Ginecol. 2019;71(4):313–320. doi:10.23736/S0026-4784.19.04397-1

44. Arrossi S, Thouyaret L, Laudi R, et al. Implementation of HPV-testing for cervical most cancers screening in programmatic contexts: the Jujuy demonstration mission in Argentina. Int J Most cancers. 2015;137(7):1709–1718. doi:10.1002/ijc.29530

45. Zhao Y, Bao H, Ma L, et al. Actual-world effectiveness of major screening with high-risk human papillomavirus testing within the cervical most cancers screening programme in China: a nationwide, population-based research. BMC Med. 2021;19(1):164. doi:10.1186/s12916-021-02026-0

46. Fontham ETH, Wolf AMD, Church TR, et al. Cervical most cancers screening for people at common danger: 2020 guideline replace from the American Most cancers Society. CA Most cancers J Clin. 2020;70(5):321–346. doi:10.3322/caac.21628

47. Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related most cancers. Nat Rev Clin Oncol. 2016;13(2):119–132. doi:10.1038/nrclinonc.2015.146

48. Arbyn M, Smith SB, Temin S, Sultana F, Citadel P; Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened ladies by utilizing HPV testing on self samples: up to date meta-analyses. BMJ. 2018;363:k4823. doi:10.1136/bmj.k4823.

49. Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Value-effectiveness research of HPV self-sampling: a scientific assessment. Prev Med. 2020;132:105953. doi:10.1016/j.ypmed.2019.105953

50. Mezei AK, Armstrong HL, Pedersen HN, et al. Value-effectiveness of cervical most cancers screening strategies in low- and middle-income international locations: a scientific assessment. Int J Most cancers. 2017;141(3):437–446. doi:10.1002/ijc.30695

51. Thomsen LT, Kjær SK. Human papillomavirus (HPV) testing for cervical most cancers screening in a middle-income nation: touch upon a big real-world implementation research in China. BMC Med. 2021;19(1):165. doi:10.1186/s12916-021-02051-z


Leave a Reply

Your email address will not be published.